XML 53 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Nature of the Business and Basis of Presentation (Details)
 1 Months Ended 2 Months Ended 3 Months Ended 5 Months Ended 8 Months Ended
Apr. 03, 2024
USD ($)
Mar. 31, 2024
USD ($)
$ / shares
shares
Feb. 06, 2024
USD ($)
$ / shares
Mar. 31, 2024
USD ($)
$ / shares
Mar. 31, 2024
USD ($)
$ / shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Aug. 29, 2024
$ / shares
Nature of the Business and Basis of Presentation [Line Items]                    
Issuance preferred stock | $       $ 3,000,000            
Convertible notes payable | $   $ 25,000,000   $ 25,000,000 $ 25,000,000          
Termination fee | $     $ 400,000              
Reverse stock split ratio     6.8569              
Common stock, par value (in Dollars per share) | $ / shares     $ 0.001     $ 0.001     $ 0.001  
Additional paid-in capital transaction costs | $ $ 20,500,000                  
Net loss per share (in Dollars per share) | $ / shares           $ (1.46)     $ (6.08)  
Common stock issued | $         $ 35,000     $ 35,000  
Common Stock exchange (in Shares) | shares             39,873,706 39,873,706    
Common stock conversion of convertible note (in Shares) | shares                 2,722,207  
Pre-funded warrants of common stock shares (in Shares) | shares                 5,522,207  
Warrants exchange (in Shares) | shares           9,664,208     9,664,208  
Net loss | $         $ (7,077,000) $ (28,623,000) $ (22,243,000)   $ (57,943,000)  
Net cash | $           39,000,000     39,000,000  
Cash and cash equivalents | $           $ 410,900,000     410,900,000  
Warrant [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Warrant gross proceeds amount | $     275,000,000              
Pre-funded Warrants [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Aggregate net proceeds | $                 $ 188,700,000  
Price per share (in Dollars per share) | $ / shares           $ 22.999     $ 22.999  
Net of issuance costs | $                 $ 11,800,000  
ARCA BIOPHARMA INC [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Termination fee | $     $ 400,000              
Maximum [Member] | Warrant [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Purchase price (in Dollars per share) | $ / shares     $ 9.71              
Per share (in Dollars per share) | $ / shares     5.55              
Minimum [Member] | Warrant [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Purchase price (in Dollars per share) | $ / shares     9.7              
Per share (in Dollars per share) | $ / shares     5.54              
Reverse Stock Split [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Net loss per share (in Dollars per share) | $ / shares         $ (2.21)   $ (6.96) $ (9.17)    
Common Stock [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Common stock, par value (in Dollars per share) | $ / shares     $ 0.001              
Common stock issued | $             $ 22,784,139 $ 22,784,139    
Common Stock exchange (in Shares) | shares           4,764,032     4,764,032  
Number of shares issued to purchase (in Shares) | shares                 680,000  
Series A Non-Voting Convertible Preferred Stock [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Purchase price | $                 $ 23,000  
Number of shares issued to purchase (in Shares) | shares                 2,439  
Series A Preferred Stock [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Net loss per share (in Dollars per share) | $ / shares           $ (1,460.62)     $ (6,077.13)  
Common stock conversion of convertible note (in Shares) | shares                 1,000  
Price per share (in Dollars per share) | $ / shares   $ 0.15   $ 0.15 $ 0.15          
Number of shares issued to purchase (in Shares) | shares   20,000,000                
Oruka common stock [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Common stock, par value (in Dollars per share) | $ / shares           0.001     $ 0.001 $ 0.001
Aggregate net proceeds | $ 275,000,000                  
Oruka pre-funded warrants [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Purchased shares of common stock | $ $ 25,000,000                  
ARCA common stock [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Exchange ratio                 6.8569  
Oruka restricted stock [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Common stock, par value (in Dollars per share) | $ / shares           0.0001     $ 0.0001  
Private Placement [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Price per share (in Dollars per share) | $ / shares           22.999     $ 22.999  
Number of shares issued to purchase (in Shares) | shares                 680,000  
Private Placement [Member] | Common Stock [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Common stock, par value (in Dollars per share) | $ / shares           $ 0.001     $ 0.001  
Number of shares purchased (in Shares) | shares           5,600,000     5,600,000  
Price per share (in Dollars per share) | $ / shares           $ 23     $ 23  
Private Placement [Member] | Series A Non-Voting Convertible Preferred Stock [Member]                    
Nature of the Business and Basis of Presentation [Line Items]                    
Preferred Stock, Convertible, Shares Issuable (in Shares) | shares           2,439     2,439